Selective HDAC1 and HDAC2 inhibitors
Provided herein are compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. Such diseases include cancer, sickle-cell anemia, beta-thalassemia, and HIV.
1. A compound selected from the group consisting of:
or pharmaceutically acceptable salts thereof.
2. A method of inhibiting the activity of HDAC1 or HDAC2 in a subject, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
3. A method of treating a disease mediated by HDAC1 or HDAC2 in a subject comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
4. The method of claim 3 , wherein the disease is a hemoglobinopathy and wherein the hemoglobinopathy is sickle-cell disease or beta-thalassemia.
5. The method of claim 3 , wherein the subject is a human.
6. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , wherein the compound is
8. A pharmaceutical composition comprising the compound of claim 6 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
9. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1 , wherein the compound is
11. A pharmaceutical composition comprising the compound of claim 9 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
12. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1 , wherein the compound is
14. A pharmaceutical composition comprising the compound of claim 12 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
15. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
16. The compound of claim 1 , wherein the compound is
17. A pharmaceutical composition comprising the compound of claim 15 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
18. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
19. The compound of claim 1 , wherein the compound is
20. A pharmaceutical composition comprising the compound of claim 18 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
21. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
22. The compound of claim 1 , wherein the compound is
23. A pharmaceutical composition comprising the compound of claim 21 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
24. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
25. The compound of claim 1 , wherein the compound is
26. A pharmaceutical composition comprising the compound of claim 24 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
27. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
28. The compound of claim 1 , wherein the compound is
29. A pharmaceutical composition comprising the compound or claim 27 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
30. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
31. The compound of claim 1 , wherein the compound is
32. A pharmaceutical composition comprising the compound of claim 30 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.